Article Type

Original Study


Objective The aim of this study was to conduct clinicopathological, treatment, and survival analysis of epithelial ovarian cancer patients treated at the Clinical Oncology Department, Menoufia University. Background Epithelial ovarian cancer constitutes the majority of ovarian neoplasms (about 80%). Predisposing factors may be genetic, personal history of breast or endometrial cancer, nulliparity, endometriosis, and postmenopausal estrogen. Symptoms are often vague, and until now there are no effective screening programs. Typically, treatment depends on a combination of surgery and chemotherapy in most of the patients. Patients and methods This study included 83 patients diagnosed with epithelial ovarian cancer presented to the Clinical Oncology Department, Menoufia University, from January 2006 until December 2011. Data were collected regarding clinicopathological characteristics, treatment modalities including surgery and chemotherapy, response to treatment, and survival analysis including progression-free survival and overall survival. Results This study included 83 patients; the mean age of the patients was 55 years. Most of the patients presented at advanced stages (stages III and IV were seen in 84.3% of the patients). Serous cystadenocarcinoma was the predominant type of tumor seen in 68.7%. Surgery was the initial step in 86.7% of the patients. Paclitaxel-carboplatin was the most commonly used regimen as first-line chemotherapy. Response rate to first-line chemotherapy reached 80.2% (35% complete response). Conclusion In our study, the age incidence of ovarian cancer was 55 years. For most of the patients, typical presentation was late. Progression-free survival was nearly the same as that reported in the western literature. There was significant correlation between response and stage. There was significant correlation between overall survival, progression-free survival, and debulking type.